Xcout IntelNewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Subscribe to see NewAmsterdam Pharma Co N.V.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NewAmsterdam Pharma Co N.V. at a glance
NewAmsterdam Pharma Co N.V. is a biotechnology company headquartered in Naarden, Netherlands. Xcout tracks 19 named people at NewAmsterdam Pharma Co N.V., including Michael Harvey Davidson FACC Facp. (CEO, President & Executive Director). Xcout recorded 15 job postings from NewAmsterdam Pharma Co N.V. in the last 90 days.
NewAmsterdam Pharma Co N.V. leadership
- Michael Harvey Davidson FACC Facp.CEO, President & Executive Director
- Douglas F. KlingChief Operating Officer
- Mayur Amrat SomaiyaChief Financial Officer
- Louise KooijChief Accounting Officer
- Juliette AudetChief Strategy & Business Officer
- Marc DitmarschChief Development Officer
13 more named people on record for NewAmsterdam Pharma Co N.V., with roles, board committees and tenure — see the full roster →
Hiring at NewAmsterdam Pharma Co N.V.
Xcout recorded 15 job postings from NewAmsterdam Pharma Co N.V. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see NewAmsterdam Pharma Co N.V.'s hiring signals →
Tech stack
NewAmsterdam Pharma Co N.V. competitors
A few of NewAmsterdam Pharma Co N.V.'s closest competitors — see the full list of competitors and alternatives →
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Gubra is a Danish biotech and contract research organization (CRO) specializing in preclinical peptide drug discovery, metabolic research, and advanced imaging services.
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
TargED Biopharmaceuticals is a Netherlands-based biotechnology company that develops first-class biological drugs to improve the treatment of thrombosis. The company utilizes small antibodies to deliver enzymes directly to blood clots, aiming to provide targeted thrombolysis for patients suffering from various thrombotic disorders.
Gemphire Therapeutics was a U.S. clinical-stage biopharmaceutical company developing gemcabene, an investigational lipid-modulating drug intended to treat dyslipidemia and related cardiovascular and metabolic conditions. It served patients with difficult-to-treat lipid disorders, including severe hypertriglyceridemia and familial hypercholesterolemia.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Get NewAmsterdam Pharma Co N.V.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NewAmsterdam Pharma Co N.V. in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access